Nautilus Biotechnolgy
NAUT
68 hedge funds and large institutions have $114M invested in Nautilus Biotechnolgy in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 7 closing their positions.
400% more call options, than puts
Call options by funds: $5K | Put options by funds: $1K
132% more capital invested
Capital invested by funds: $48.9M → $114M (+$64.8M)
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
0.31% more ownership
Funds ownership: 45.84% → 46.16% (+0.31%)
0% more funds holding
Funds holding: 68 → 68 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ST
Sentinel Trust
Houston,
Texas
|
+$1.23M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$605K |
| 3 |
Goldman Sachs
New York
|
+$295K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$273K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$192K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.23M |
| 2 |
Corient Private Wealth
Miami,
Florida
|
-$335K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$254K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$222K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$215K |
NAUT Hedge Fund Activity: Q4 2025 in Review
68 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q4 2025, worth a combined $114M — up 132% from $48.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new NAUT positions and 7 closed out — a net gain of 4 holders — while 18 added to existing stakes and 15 trimmed.
The largest buyer was Sentinel Trust, opening a new position worth an estimated $1.23M. The largest seller was Renaissance Technologies, cutting an estimated $1.23M.
- 68 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $114M of Nautilus Biotechnolgy stock for Q4 2025, up 132% quarter-over-quarter.
- 11 funds opened new Nautilus Biotechnolgy positions in Q4 2025 and 7 closed out, a net change of +4 holders.
- The largest Nautilus Biotechnolgy buyer in Q4 2025 was Sentinel Trust, an estimated $1.23M added.
- The largest Nautilus Biotechnolgy seller in Q4 2025 was Renaissance Technologies, an estimated $1.23M sold.
Based on aggregated 13F filings for Q4 2025.